Suppr超能文献

探索外泌体疗法的监管框架:见解与观点

Exploring Regulatory Frameworks for Exosome Therapy: Insights and Perspectives.

作者信息

Li Qiushi, Li Yuxia, Shao Jiaqing, Sun Jianhua, Hu Lan, Yun Xia, Liuqing Chen, Gong Likun, Wu Shuxia

机构信息

AIE Bioscience (Guangdong) Co. Ltd. Zhongshan China.

Department of Immunoassay and Immunochemistry, State Key Laboratory of Drug Research, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China.

出版信息

Health Care Sci. 2025 Aug 4;4(4):299-309. doi: 10.1002/hcs2.70028. eCollection 2025 Aug.

Abstract

Extracellular vesicles (EVs) have emerged as a promising technology for diagnostic and therapeutic applications in clinical settings over the past decade. However, their advancement is hindered by complex technological and regulatory challenges. This review outlines key considerations in the manufacturing process, quality management, and nonclinical evaluation relevant to EV-based drug development. Furthermore, we summarize and compare technical regulatory requirements across major countries to help clarify the regulatory principles governing EV products. Our analysis reveals an ongoing international debate regarding the regulatory review of EVs. Nevertheless, adopting a risk-based classification framework that categorizes EV products as advanced therapeutic drugs is a rational approach. Critical challenges include the development of standardized production protocols, a clearer understanding of therapeutic mechanisms, and resolving complex regulatory issues.

摘要

在过去十年中,细胞外囊泡(EVs)已成为临床诊断和治疗应用中一项很有前景的技术。然而,其发展受到复杂的技术和监管挑战的阻碍。本综述概述了与基于EV的药物开发相关的制造过程、质量管理和非临床评估中的关键考虑因素。此外,我们总结并比较了主要国家的技术监管要求,以帮助阐明管理EV产品的监管原则。我们的分析揭示了关于EVs监管审查的国际争论仍在进行。尽管如此,采用将EV产品归类为先进治疗药物的基于风险的分类框架是一种合理的方法。关键挑战包括制定标准化生产方案、更清楚地了解治疗机制以及解决复杂的监管问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4177/12371722/7d2cbf2042cf/HCS2-4-299-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验